{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:22:48Z","timestamp":1791411768761,"version":"4.3.3"},"reference-count":216,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41574-018-0118-x","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T16:25:17Z","timestamp":1542385517000},"page":"90-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-9667","authenticated-orcid":false,"given":"Christoffer","family":"Clemmensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Finan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo D.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"DiMarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias H.","family":"Tsch\u00f6p","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna M.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"118_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMra1514009","volume":"376","author":"SB Heymsfield","year":"2017","unstructured":"Heymsfield, S. B. & Wadden, T. A. Mechanisms, pathophysiology, and management of obesity. N. Engl. J. Med. 376, 254\u2013266 (2017).","journal-title":"N. Engl. J. Med."},{"key":"118_CR2","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/cphy.c110025","volume":"2","author":"FW Booth","year":"2012","unstructured":"Booth, F. W., Roberts, C. K. & Laye, M. J. Lack of exercise is a major cause of chronic diseases. Compr. Physiol. 2, 1143\u20131211 (2012).","journal-title":"Compr. Physiol."},{"key":"118_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1467-789X.2009.00708.x","volume":"12","author":"AG Tsai","year":"2011","unstructured":"Tsai, A. G., Williamson, D. F. & Glick, H. A. Direct medical cost of overweight and obesity in the USA: a\u00a0quantitative systematic review. Obes. Rev. 12, 50\u201361 (2011).","journal-title":"Obes. Rev."},{"key":"118_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nm0106-62","volume":"12","author":"D Yach","year":"2006","unstructured":"Yach, D., Stuckler, D. & Brownell, K. D. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat. Med. 12, 62\u201366 (2006).","journal-title":"Nat. Med."},{"key":"118_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cell.2015.02.023","volume":"161","author":"L Gautron","year":"2015","unstructured":"Gautron, L., Elmquist, J. K. & Williams, K. W. Neural control of energy balance: translating circuits to therapies. Cell 161, 133\u2013145 (2015).","journal-title":"Cell"},{"key":"118_CR6","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2017.01.025","volume":"168","author":"C Clemmensen","year":"2017","unstructured":"Clemmensen, C. et al. Gut-brain cross-talk in metabolic control. Cell 168, 758\u2013774 (2017).","journal-title":"Cell"},{"key":"118_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/372425a0","volume":"372","author":"Y Zhang","year":"1994","unstructured":"Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425\u2013432 (1994).","journal-title":"Nature"},{"key":"118_CR8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/382250a0","volume":"382","author":"RS Ahima","year":"1996","unstructured":"Ahima, R. S. et al. Role of leptin in the neuroendocrine response to fasting. Nature 382, 250\u2013252 (1996).","journal-title":"Nature"},{"key":"118_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/45230","volume":"402","author":"M Kojima","year":"1999","unstructured":"Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656\u2013660 (1999).","journal-title":"Nature"},{"key":"118_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/35038090","volume":"407","author":"M Tschop","year":"2000","unstructured":"Tschop, M., Smiley, D. L. & Heiman, M. L. Ghrelin induces adiposity in rodents. Nature 407, 908\u2013913 (2000).","journal-title":"Nature"},{"key":"118_CR11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1172\/JCI112855","volume":"79","author":"S Mojsov","year":"1987","unstructured":"Mojsov, S., Weir, G. C. & Habener, J. F. Insulinotropin: glucagon-like peptide I (7\u201337) co-encoded in the\u00a0glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 79, 616\u2013619 (1987).","journal-title":"J. Clin. Invest."},{"key":"118_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","volume":"211","author":"JJ Holst","year":"1987","unstructured":"Holst, J. J., Orskov, C., Nielsen, O. V. & Schwartz, T. W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 211, 169\u2013174 (1987).","journal-title":"FEBS Lett."},{"key":"118_CR13","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","volume":"2","author":"B Kreymann","year":"1987","unstructured":"Kreymann, B., Williams, G., Ghatei, M. A. & Bloom, S. R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2, 1300\u20131304 (1987).","journal-title":"Lancet"},{"key":"118_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/379069a0","volume":"379","author":"MD Turton","year":"1996","unstructured":"Turton, M. D. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69\u201372 (1996).","journal-title":"Nature"},{"key":"118_CR15","first-page":"R848","volume":"271","author":"M Tang-Christensen","year":"1996","unstructured":"Tang-Christensen, M. et al. Central administration of GLP-1-(7\u201336) amide inhibits food and water intake in rats. Am. J. Physiol. 271, R848\u2013R856 (1996).","journal-title":"Am. J. Physiol."},{"key":"118_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/JCI990","volume":"101","author":"A Flint","year":"1998","unstructured":"Flint, A., Raben, A., Astrup, A. & Holst, J. J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101, 515\u2013520 (1998).","journal-title":"J. Clin. Invest."},{"key":"118_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer, X. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373, 11\u201322 (2015).","journal-title":"N. Engl. J. Med."},{"key":"118_CR18","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux, C. W. et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389, 1399\u20131409 (2017).","journal-title":"Lancet"},{"key":"118_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"118_CR20","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/dom.12963","volume":"19","author":"PM O\u2019Neil","year":"2017","unstructured":"O\u2019Neil, P. M. et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes. Metab. 19, 1529\u20131536 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"118_CR21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128 (2015).","journal-title":"N. Engl. J. Med."},{"key":"118_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004007","volume":"6","author":"M Mazidi","year":"2017","unstructured":"Mazidi, M., Rezaie, P., Gao, H. K. & Kengne, A. P. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J. Am. Heart Assoc. 6, e004007 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"118_CR23","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","volume":"6","author":"B Ludvik","year":"2018","unstructured":"Ludvik, B. et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 6, 370\u2013381 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"118_CR24","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Frias","year":"2016","unstructured":"Frias, J. P. et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 4, 1004\u20131016 (2016).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"118_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S2213-8587(13)70218-3","volume":"2","author":"S Madsbad","year":"2014","unstructured":"Madsbad, S., Dirksen, C. & Holst, J. J. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2, 152\u2013164 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"118_CR26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nrcardio.2016.162","volume":"13","author":"AJ Beamish","year":"2016","unstructured":"Beamish, A. J., Olbers, T., Kelly, A. S. & Inge, T. H. Cardiovascular effects of bariatric surgery. Nat. Rev. Cardiol. 13, 730\u2013743 (2016).","journal-title":"Nat. Rev. Cardiol."},{"key":"118_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cmet.2015.01.001","volume":"21","author":"RJ Seeley","year":"2015","unstructured":"Seeley, R. J., Chambers, A. P. & Sandoval, D. A. The\u00a0role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab. 21, 369\u2013378 (2015).","journal-title":"Cell Metab."},{"key":"118_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/jama.2017.20051","volume":"319","author":"SZ Yanovski","year":"2018","unstructured":"Yanovski, S. Z. & Yanovski, J. A. Toward precision approaches for the prevention and treatment of obesity. JAMA 319, 223\u2013224 (2018).","journal-title":"JAMA"},{"key":"118_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2337\/dc14-1630","volume":"38","author":"L Van Gaal","year":"2015","unstructured":"Van Gaal, L. & Scheen, A. Weight management in type\u00a02 diabetes: current and emerging approaches to treatment. Diabetes Care 38, 1161\u20131172 (2015).","journal-title":"Diabetes Care"},{"key":"118_CR30","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.2337\/db12-1498","volume":"62","author":"HE Wilson-Perez","year":"2013","unstructured":"Wilson-Perez, H. E. et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency. Diabetes 62, 2380\u20132385 (2013).","journal-title":"Diabetes"},{"key":"118_CR31","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M Zander","year":"2002","unstructured":"Zander, M., Madsbad, S., Madsen, J. L. & Holst, J. J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359, 824\u2013830 (2002).","journal-title":"Lancet"},{"key":"118_CR32","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsboll","year":"2012","unstructured":"Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K. & Gluud, L. L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344, d7771 (2012).","journal-title":"BMJ"},{"key":"118_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J. & Nauck, M. A. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes. Metab. 19, 336\u2013347 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"118_CR34","doi-asserted-by":"publisher","first-page":"R562","DOI":"10.1152\/ajpregu.00599.2003","volume":"287","author":"JP Gutzwiller","year":"2004","unstructured":"Gutzwiller, J. P., Degen, L., Matzinger, D., Prestin, S. & Beglinger, C. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287, R562\u2013R567 (2004).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"118_CR35","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1210\/en.2005-0237","volume":"146","author":"NM Neary","year":"2005","unstructured":"Neary, N. M. et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146, 5120\u20135127 (2005).","journal-title":"Endocrinology"},{"key":"118_CR36","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2337\/db12-0797","volume":"62","author":"TM Tan","year":"2013","unstructured":"Tan, T. M. et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62, 1131\u20131138 (2013).","journal-title":"Diabetes"},{"key":"118_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.regpep.2013.03.025","volume":"184","author":"KB Madsen","year":"2013","unstructured":"Madsen, K. B. et al. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. Regul. Pept. 184, 30\u201339 (2013).","journal-title":"Regul. Pept."},{"key":"118_CR38","doi-asserted-by":"publisher","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","volume":"5","author":"B Finan","year":"2013","unstructured":"Finan, B. et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl Med. 5, 209ra151 (2013).","journal-title":"Sci. Transl Med."},{"key":"118_CR39","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.2337\/db08-0688","volume":"57","author":"WL Suarez-Pinzon","year":"2008","unstructured":"Suarez-Pinzon, W. L. et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57, 3281\u20133288 (2008).","journal-title":"Diabetes"},{"key":"118_CR40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1210\/en.2015-1600","volume":"157","author":"KV Grunddal","year":"2016","unstructured":"Grunddal, K. V. et al. Neurotensin is coexpressed, coreleased, and acts together with GLP-1 and PYY in enteroendocrine control of metabolism. Endocrinology 157, 176\u2013194 (2016).","journal-title":"Endocrinology"},{"key":"118_CR41","first-page":"S1","volume":"54","author":"[No authors listed.]","year":"2011","unstructured":"[No authors listed.] Abstracts of the 47th annual meeting of the European Association for the Study of Diabetes. September 16, 2011. Lisbon, Portugal. Diabetologia 54, S1\u2013S543 (2011).","journal-title":"Diabetologia"},{"key":"118_CR42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.15252\/emmm.201404508","volume":"7","author":"C Clemmensen","year":"2015","unstructured":"Clemmensen, C. et al. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. EMBO Mol. Med. 7, 288\u2013298 (2015).","journal-title":"EMBO Mol. Med."},{"key":"118_CR43","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/dom.12025","volume":"15","author":"R Balena","year":"2013","unstructured":"Balena, R., Hensley, I. E., Miller, S. & Barnett, A. H. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes. Metab. 15, 485\u2013502 (2013).","journal-title":"Diabetes Obes. Metab."},{"key":"118_CR44","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1152\/physrev.00025.2016","volume":"97","author":"TD Muller","year":"2017","unstructured":"Muller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D. & Tschop, M. H. The new biology and pharmacology of\u00a0glucagon. Physiol. Rev. 97, 721\u2013766 (2017).","journal-title":"Physiol. Rev."},{"key":"118_CR45","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.celrep.2018.01.065","volume":"22","author":"AX Sharma","year":"2018","unstructured":"Sharma, A. X. et al. Glucagon receptor antagonism improves glucose metabolism and cardiac function by promoting AMP-mediated protein kinase in diabetic mice. Cell Rep. 22, 1760\u20131773 (2018).","journal-title":"Cell Rep."},{"key":"118_CR46","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/dom.13202","volume":"20","author":"J Pettus","year":"2018","unstructured":"Pettus, J. et al. Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: a randomized controlled trial. Diabetes Obes. Metab. 20, 1302\u20131305 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"118_CR47","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/dom.12958","volume":"19","author":"CB Guzman","year":"2017","unstructured":"Guzman, C. B. et al. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Diabetes Obes. Metab. 19, 1521\u20131528 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"118_CR48","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/dom.12904","volume":"19","author":"CM Kazda","year":"2017","unstructured":"Kazda, C. M. et al. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory\u00a0blood pressure in patients with type 2 diabetes. Diabetes Obes. Metab. 19, 1071\u20131077 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"118_CR49","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2337\/dc15-1643","volume":"39","author":"CM Kazda","year":"2016","unstructured":"Kazda, C. M. et al. Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase\u00a02 studies. Diabetes Care 39, 1241\u20131249 (2016).","journal-title":"Diabetes Care"},{"key":"118_CR50","doi-asserted-by":"publisher","first-page":"30121","DOI":"10.1016\/S0021-9258(18)43785-4","volume":"269","author":"SA Hjorth","year":"1994","unstructured":"Hjorth, S. A., Adelhorst, K., Pedersen, B. B., Kirk, O. & Schwartz, T. W. Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. J. Biol. Chem. 269, 30121\u201330124 (1994).","journal-title":"J. Biol. Chem."},{"key":"118_CR51","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nchembio.209","volume":"5","author":"JW Day","year":"2009","unstructured":"Day, J. W. et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5, 749\u2013757 (2009).","journal-title":"Nat. Chem. Biol."},{"key":"118_CR52","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.2337\/db09-0278","volume":"58","author":"A Pocai","year":"2009","unstructured":"Pocai, A. et al. Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58, 2258\u20132266 (2009).","journal-title":"Diabetes"},{"key":"118_CR53","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1021\/acs.jmedchem.7b00174","volume":"60","author":"A Evers","year":"2017","unstructured":"Evers, A. et al. Design of novel exendin-based dual glucagon-like peptide 1 (GLP-1)\/glucagon receptor agonists. J. Med. Chem. 60, 4293\u20134303 (2017).","journal-title":"J. Med. Chem."},{"key":"118_CR54","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/dom.12735","volume":"18","author":"SJ Henderson","year":"2016","unstructured":"Henderson, S. J. et al. Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes. Metab. 18, 1176\u20131190 (2016).","journal-title":"Diabetes Obes. Metab."},{"key":"118_CR55","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1021\/acs.jmedchem.8b00292","volume":"61","author":"A Evers","year":"2018","unstructured":"Evers, A. et al. Dual glucagon-like peptide 1 (GLP-1)\/glucagon receptor agonists specifically optimized for multidose formulations. J. Med. Chem. 61, 5580\u20135593 (2018).","journal-title":"J. Med. Chem."},{"key":"118_CR56","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s00125-017-4354-8","volume":"60","author":"MA Sanchez-Garrido","year":"2017","unstructured":"Sanchez-Garrido, M. A. et al. GLP-1\/glucagon receptor co-agonism for treatment of obesity. Diabetologia 60, 1851\u20131861 (2017).","journal-title":"Diabetologia"},{"key":"118_CR57","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","volume":"391","author":"P Ambery","year":"2018","unstructured":"Ambery, P. et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 391, 2607\u20132618 (2018).","journal-title":"Lancet"},{"key":"118_CR58","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molmed.2016.03.005","volume":"22","author":"B Finan","year":"2016","unstructured":"Finan, B. et al. Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol. Med. 22, 359\u2013376 (2016).","journal-title":"Trends Mol. Med."},{"key":"118_CR59","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nm727","volume":"8","author":"K Miyawaki","year":"2002","unstructured":"Miyawaki, K. et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8, 738\u2013742 (2002).","journal-title":"Nat. Med."},{"key":"118_CR60","doi-asserted-by":"publisher","first-page":"E1746","DOI":"10.1152\/ajpendo.00460.2007","volume":"293","author":"PL McClean","year":"2007","unstructured":"McClean, P. L. et al. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am. J. Physiol. Endocrinol. Metab. 293, E1746\u2013E1755 (2007).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"118_CR61","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm.3997","volume":"22","author":"JE Campbell","year":"2016","unstructured":"Campbell, J. E. et al. TCF1 links GIPR signaling to the control of beta cell function and survival. Nat. Med. 22, 84\u201390 (2016).","journal-title":"Nat. Med."},{"key":"118_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/bph.13323","volume":"173","author":"AH Sparre-Ulrich","year":"2016","unstructured":"Sparre-Ulrich, A. H. et al. Species-specific action of (Pro3)GIP \u2014 a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br. J. Pharmacol. 173, 27\u201338 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"118_CR63","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1210\/jc.2016-1933","volume":"101","author":"M Asmar","year":"2016","unstructured":"Asmar, M. et al. Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans. J. Clin. Endocrinol. Metab. 101, 3155\u20133162 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"118_CR64","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.2337\/db17-0480","volume":"66","author":"M Asmar","year":"2017","unstructured":"Asmar, M. et al. The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor. Diabetes 66, 2363\u20132371 (2017).","journal-title":"Diabetes"},{"key":"118_CR65","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1172\/JCI116186","volume":"91","author":"MA Nauck","year":"1993","unstructured":"Nauck, M. A. et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of\u00a0synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91, 301\u2013307 (1993).","journal-title":"J. Clin. Invest."},{"key":"118_CR66","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","volume":"52","author":"PV Hojberg","year":"2009","unstructured":"Hojberg, P. V. et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52, 199\u2013207 (2009).","journal-title":"Diabetologia"},{"key":"118_CR67","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/dom.13034","volume":"20","author":"PK Norregaard","year":"2018","unstructured":"Norregaard, P. K. et al. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents. Diabetes Obes. Metab. 20, 60\u201368 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"118_CR68","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","volume":"26","author":"JP Frias","year":"2017","unstructured":"Frias, J. P. et al. The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab. 26, 343\u2013352 (2017).","journal-title":"Cell Metab."},{"key":"118_CR69","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/dom.13024","volume":"19","author":"C Schmitt","year":"2017","unstructured":"Schmitt, C., Portron, A., Jadidi, S., Sarkar, N. & DiMarchi, R. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes. Metab. 19, 1436\u20131445 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"118_CR70","doi-asserted-by":"publisher","unstructured":"Coskun, T. et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol. Metab. https:\/\/doi.org\/10.1016\/j.molmet.2018.09.009 (2018).","DOI":"10.1016\/j.molmet.2018.09.009"},{"key":"118_CR71","doi-asserted-by":"publisher","unstructured":"Frias, J. P. et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(18)32260-8 (2018).","DOI":"10.1016\/S0140-6736(18)32260-8"},{"key":"118_CR72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","volume":"21","author":"B Finan","year":"2015","unstructured":"Finan, B. et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27\u201336 (2015).","journal-title":"Nat. Med."},{"key":"118_CR73","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molmet.2017.02.002","volume":"6","author":"S Jall","year":"2017","unstructured":"Jall, S. et al. Monomeric GLP-1\/GIP\/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol. Metab. 6, 440\u2013446 (2017).","journal-title":"Mol. Metab."},{"key":"118_CR74","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2016.06.021","volume":"24","author":"MH Tschop","year":"2016","unstructured":"Tschop, M. H. et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 24, 51\u201362 (2016).","journal-title":"Cell Metab."},{"key":"118_CR75","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/MCG.0000000000000604","volume":"51","author":"B Kochar","year":"2017","unstructured":"Kochar, B. et al. Safety and efficacy of teduglutide (Gattex) in patients with Crohn\u2019s disease and need for parenteral support due to short bowel syndrome-associated intestinal failure. J. Clin. Gastroenterol. 51, 508\u2013511 (2017).","journal-title":"J. Clin. Gastroenterol."},{"key":"118_CR76","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/gut.2008.165886","volume":"58","author":"PD Cani","year":"2009","unstructured":"Cani, P. D. et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091\u20131103 (2009).","journal-title":"Gut"},{"key":"118_CR77","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.physbeh.2018.03.004","volume":"192","author":"P Wismann","year":"2018","unstructured":"Wismann, P. et al. Novel GLP-1\/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice. Physiol. Behav. 192, 72\u201381 (2018).","journal-title":"Physiol. Behav."},{"key":"118_CR78","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cmet.2016.01.003","volume":"23","author":"DA Winer","year":"2016","unstructured":"Winer, D. A., Luck, H., Tsai, S. & Winer, S. The intestinal immune system in obesity and insulin resistance. Cell Metab. 23, 413\u2013426 (2016).","journal-title":"Cell Metab."},{"key":"118_CR79","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/npp.2010.178","volume":"36","author":"CY Cheng","year":"2011","unstructured":"Cheng, C. Y., Chu, J. Y. & Chow, B. K. Central and peripheral administration of secretin inhibits food intake in mice through the activation of the melanocortin system. Neuropsychopharmacology 36, 459\u2013471 (2011).","journal-title":"Neuropsychopharmacology"},{"key":"118_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065696","volume":"8","author":"CF Hansen","year":"2013","unstructured":"Hansen, C. F. et al. Hypertrophy dependent doubling of L-cells in Roux-en-Y gastric bypass operated rats. PLOS ONE 8, e65696 (2013).","journal-title":"PLOS ONE"},{"key":"118_CR81","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/psc.3048","volume":"23","author":"SB van Witteloostuijn","year":"2017","unstructured":"van Witteloostuijn, S. B. et al. GUB06-046, a novel secretin\/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice. J. Pept. Sci. 23, 845\u2013854 (2017).","journal-title":"J. Pept. Sci."},{"key":"118_CR82","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/0006-8993(91)91644-G","volume":"539","author":"WT Chance","year":"1991","unstructured":"Chance, W. T., Balasubramaniam, A., Zhang, F. S., Wimalawansa, S. J. & Fischer, J. E. Anorexia following the intrahypothalamic administration of amylin. Brain Res. 539, 352\u2013354 (1991).","journal-title":"Brain Res."},{"key":"118_CR83","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00198-007-0490-1","volume":"19","author":"CH Chesnut 3rd","year":"2008","unstructured":"Chesnut, C. H. 3rd et al. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos. Int. 19, 479\u2013491 (2008).","journal-title":"Osteoporos. Int."},{"key":"118_CR84","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.1152\/ajpendo.00121.2014","volume":"307","author":"KV Andreassen","year":"2014","unstructured":"Andreassen, K. V. et al. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats. Am. J. Physiol. Endocrinol. Metab. 307, E24\u2013E33 (2014).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"118_CR85","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ejphar.2015.05.051","volume":"762","author":"ST Hjuler","year":"2015","unstructured":"Hjuler, S. T., Andreassen, K. V., Gydesen, S., Karsdal,\u00a0M. A. & Henriksen, K. KBP-042 improves bodyweight and glucose homeostasis with indices of\u00a0increased insulin sensitivity irrespective of route of administration. Eur. J. Pharmacol. 762, 229\u2013238 (2015).","journal-title":"Eur. J. Pharmacol."},{"key":"118_CR86","doi-asserted-by":"publisher","first-page":"E821","DOI":"10.1152\/ajpendo.00514.2015","volume":"310","author":"S Gydesen","year":"2016","unstructured":"Gydesen, S. et al. KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight. Am.\u00a0J. Physiol. Endocrinol. Metab. 310, E821\u2013E827 (2016).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"118_CR87","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/oby.21563","volume":"24","author":"ST Hjuler","year":"2016","unstructured":"Hjuler, S. T. et al. The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity. Obesity 24, 1712\u20131722 (2016).","journal-title":"Obesity"},{"key":"118_CR88","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/bph.13723","volume":"174","author":"S Gydesen","year":"2017","unstructured":"Gydesen, S. et al. A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br. J. Pharmacol. 174, 591\u2013602 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"118_CR89","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2337\/diabetes.51.3.686","volume":"51","author":"I Rooman","year":"2002","unstructured":"Rooman, I., Lardon, J. & Bouwens, L. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 51, 686\u2013690 (2002).","journal-title":"Diabetes"},{"key":"118_CR90","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1177\/002215540305101110","volume":"51","author":"J Morisset","year":"2003","unstructured":"Morisset, J., Julien, S. & Laine, J. Localization of cholecystokinin receptor subtypes in the endocine pancreas. J. Histochem. Cytochem. 51, 1501\u20131513 (2003).","journal-title":"J. Histochem. Cytochem."},{"key":"118_CR91","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1463-1326.2012.01676.x","volume":"15","author":"K Fosgerau","year":"2013","unstructured":"Fosgerau, K. et al. The novel GLP-1-gastrin dual agonist, ZP3022, increases beta-cell mass and prevents diabetes in db\/db mice. Diabetes Obes. Metab. 15, 62\u201371 (2013).","journal-title":"Diabetes Obes. Metab."},{"key":"118_CR92","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1124\/jpet.114.215293","volume":"350","author":"LS Dalboge","year":"2014","unstructured":"Dalboge, L. S. et al. The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases beta-cell mass without affecting islet number\u00a0in db\/db mice. J. Pharmacol. Exp. Ther. 350, 353\u2013360 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"118_CR93","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.peptides.2015.03.024","volume":"69","author":"J Skarbaliene","year":"2015","unstructured":"Skarbaliene, J. et al. The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats. Peptides 69, 47\u201355 (2015).","journal-title":"Peptides"},{"key":"118_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078154","volume":"8","author":"JL Trevaskis","year":"2013","unstructured":"Trevaskis, J. L. et al. Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. PLOS ONE 8, e78154 (2013).","journal-title":"PLOS ONE"},{"key":"118_CR95","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1124\/jpet.117.241281","volume":"362","author":"ST Hjuler","year":"2017","unstructured":"Hjuler, S. T., Gydesen, S., Andreassen, K. V., Karsdal, M. A. & Henriksen, K. The dual amylin- and calcitonin-receptor agonist KBP-042 works as adjunct to metformin on fasting hyperglycemia and HbA1c in a rat model of type 2 diabetes. J. Pharmacol. Exp. Ther. 362, 24\u201330 (2017).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"118_CR96","doi-asserted-by":"publisher","first-page":"E598","DOI":"10.1152\/ajpendo.00419.2016","volume":"313","author":"S Gydesen","year":"2017","unstructured":"Gydesen, S. et al. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog. Am. J. Physiol. Endocrinol. Metab. 313, E598\u2013E607 (2017).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"118_CR97","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nrd.2017.226","volume":"17","author":"SA Dugger","year":"2018","unstructured":"Dugger, S. A., Platt, A. & Goldstein, D. B. Drug development in the era of precision medicine. Nat. Rev. Drug Discov. 17, 183\u2013196 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"118_CR98","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nm1525","volume":"13","author":"Q Gao","year":"2007","unstructured":"Gao, Q. et al. Anorectic estrogen mimics leptin\u2019s effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. Nat. Med. 13, 89\u201394 (2007).","journal-title":"Nat. Med."},{"key":"118_CR99","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cmet.2014.03.031","volume":"20","author":"PB Martinez de Morentin","year":"2014","unstructured":"Martinez de Morentin, P. B. et al. Estradiol regulates brown adipose tissue thermogenesis via hypothalamic AMPK. Cell Metab. 20, 41\u201353 (2014).","journal-title":"Cell Metab."},{"key":"118_CR100","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1074\/jbc.M117.805069","volume":"293","author":"Z Zhou","year":"2018","unstructured":"Zhou, Z. et al. Estrogen receptor alpha protects pancreatic beta-cells from apoptosis by preserving mitochondrial function and suppressing endoplasmic reticulum stress. J. Biol. Chem. 293, 4735\u20134751 (2018).","journal-title":"J. Biol. Chem."},{"key":"118_CR101","doi-asserted-by":"publisher","first-page":"334ra54","DOI":"10.1126\/scitranslmed.aad3815","volume":"8","author":"V Ribas","year":"2016","unstructured":"Ribas, V. et al. Skeletal muscle action of estrogen receptor alpha is critical for the maintenance of mitochondrial function and metabolic homeostasis in females. Sci. Transl Med. 8, 334ra54 (2016).","journal-title":"Sci. Transl Med."},{"key":"118_CR102","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/nm.3009","volume":"18","author":"B Finan","year":"2012","unstructured":"Finan, B. et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18, 1847\u20131856 (2012).","journal-title":"Nat. Med."},{"key":"118_CR103","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1172\/JCI74726","volume":"124","author":"X Cao","year":"2014","unstructured":"Cao, X. et al. Estrogens stimulate serotonin neurons to inhibit binge-like eating in mice. J. Clin. Invest. 124, 4351\u20134362 (2014).","journal-title":"J. Clin. Invest."},{"key":"118_CR104","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuropharm.2016.07.039","volume":"110","author":"H Vogel","year":"2016","unstructured":"Vogel, H. et al. GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight. Neuropharmacology 110, 396\u2013406 (2016).","journal-title":"Neuropharmacology"},{"key":"118_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/srep10211","volume":"5","author":"JP Tiano","year":"2015","unstructured":"Tiano, J. P., Tate, C. R., Yang, B. S., DiMarchi, R. & Mauvais-Jarvis, F. Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis. Sci. Rep. 5, 10211 (2015).","journal-title":"Sci. Rep."},{"key":"118_CR106","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s00125-014-3478-3","volume":"58","author":"RW Schwenk","year":"2015","unstructured":"Schwenk, R. W. et al. GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia 58, 604\u2013614 (2015).","journal-title":"Diabetologia"},{"key":"118_CR107","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrd4275","volume":"13","author":"MY Donath","year":"2014","unstructured":"Donath, M. Y. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat. Rev. Drug Discov. 13, 465\u2013476 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"118_CR108","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.cmet.2017.08.023","volume":"26","author":"C Quarta","year":"2017","unstructured":"Quarta, C. et al. Molecular integration of incretin and glucocorticoid action reverses immunometabolic dysfunction and obesity. Cell Metab. 26, 620\u2013632 (2017).","journal-title":"Cell Metab."},{"key":"118_CR109","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.cmet.2017.06.014","volume":"26","author":"N Martinez-Sanchez","year":"2017","unstructured":"Martinez-Sanchez, N. et al. Hypothalamic AMPK-ER stress-JNK1 axis mediates the central actions of thyroid hormones on energy balance. Cell Metab. 26, 212\u2013229 (2017).","journal-title":"Cell Metab."},{"key":"118_CR110","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.celrep.2015.10.022","volume":"13","author":"JZ Lin","year":"2015","unstructured":"Lin, J. Z. et al. Pharmacological activation of thyroid hormone receptors elicits a functional conversion of white to brown fat. Cell Rep. 13, 1528\u20131537 (2015).","journal-title":"Cell Rep."},{"key":"118_CR111","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrendo.2018.10","volume":"14","author":"RA Sinha","year":"2018","unstructured":"Sinha, R. A., Singh, B. K. & Yen, P. M. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat. Rev. Endocrinol. 14, 259\u2013269 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"118_CR112","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199602013340503","volume":"334","author":"RV Considine","year":"1996","unstructured":"Considine, R. V. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334, 292\u2013295 (1996).","journal-title":"N. Engl. J. Med."},{"key":"118_CR113","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","volume":"282","author":"SB Heymsfield","year":"1999","unstructured":"Heymsfield, S. B. et al. Recombinant leptin for weight\u00a0loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282, 1568\u20131575 (1999).","journal-title":"JAMA"},{"key":"118_CR114","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3945\/ajcn.111.012385","volume":"95","author":"HR Kissileff","year":"2012","unstructured":"Kissileff, H. R. et al. Leptin reverses declines in satiation in weight-reduced obese humans. Am. J. Clin.\u00a0Nutr. 95, 309\u2013317 (2012).","journal-title":"Am. J. Clin. Nutr."},{"key":"118_CR115","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1172\/JCI25977","volume":"115","author":"M Rosenbaum","year":"2005","unstructured":"Rosenbaum, M. et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J. Clin. Invest. 115, 3579\u20133586 (2005).","journal-title":"J. Clin. Invest."},{"key":"118_CR116","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1210\/jcem.87.5.8628","volume":"87","author":"M Rosenbaum","year":"2002","unstructured":"Rosenbaum, M., Murphy, E. M., Heymsfield, S. B., Matthews, D. E. & Leibel, R. L. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J. Clin. Endocrinol. Metab. 87, 2391\u20132394 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"118_CR117","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s00125-016-3906-7","volume":"59","author":"C Quarta","year":"2016","unstructured":"Quarta, C., Sanchez-Garrido, M. A., Tschop, M. H. &\u00a0Clemmensen, C. Renaissance of leptin for obesity therapy. Diabetologia 59, 920\u2013927 (2016).","journal-title":"Diabetologia"},{"key":"118_CR118","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1053\/meta.2002.31332","volume":"51","author":"B Fruehwald-Schultes","year":"2002","unstructured":"Fruehwald-Schultes, B. et al. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in\u00a0normal-weight healthy men. Metabolism 51, 531\u2013536 (2002).","journal-title":"Metabolism"},{"key":"118_CR119","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2337\/diabetes.55.03.06.db05-0917","volume":"55","author":"YW Kim","year":"2006","unstructured":"Kim, Y. W. et al. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 55, 716\u2013724 (2006).","journal-title":"Diabetes"},{"key":"118_CR120","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1677\/joe.1.05646","volume":"183","author":"J Klein","year":"2004","unstructured":"Klein, J. et al. Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes. J. Endocrinol. 183, 299\u2013307 (2004).","journal-title":"J. Endocrinol."},{"key":"118_CR121","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.metabol.2010.02.007","volume":"60","author":"G Aubert","year":"2011","unstructured":"Aubert, G., Mansuy, V., Voirol, M. J., Pellerin, L. & Pralong, F. P. The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism 60, 327\u2013334 (2011).","journal-title":"Metabolism"},{"key":"118_CR122","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.1073\/pnas.0706473105","volume":"105","author":"JD Roth","year":"2008","unstructured":"Roth, J. D. et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl Acad. Sci. USA 105, 7257\u20137262 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"118_CR123","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/oby.2009.184","volume":"17","author":"E Ravussin","year":"2009","unstructured":"Ravussin, E. et al. Enhanced weight loss with pramlintide\/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17, 1736\u20131743 (2009).","journal-title":"Obesity"},{"key":"118_CR124","doi-asserted-by":"publisher","first-page":"E1116","DOI":"10.1152\/ajpendo.00087.2015","volume":"308","author":"EG Mietlicki-Baase","year":"2015","unstructured":"Mietlicki-Baase, E. G., Olivos, D. R., Jeffrey, B. A. & Hayes, M. R. Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake. Am. J. Physiol. Endocrinol. Metab. 308, E1116\u2013E1122 (2015).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"118_CR125","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1210\/en.2009-0546","volume":"151","author":"VF Turek","year":"2010","unstructured":"Turek, V. F. et al. Mechanisms of amylin\/leptin synergy in rodent models. Endocrinology 151, 143\u2013152 (2010).","journal-title":"Endocrinology"},{"key":"118_CR126","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/osp4.62","volume":"2","author":"JL Trevaskis","year":"2016","unstructured":"Trevaskis, J. L. et al. Amylin\/leptin synergy is absent in extreme obesity and not restored by calorie restriction-induced weight loss in rats. Obes. Sci. Pract. 2, 385\u2013391 (2016).","journal-title":"Obes. Sci. Pract."},{"key":"118_CR127","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/psc.2408","volume":"18","author":"TD Muller","year":"2012","unstructured":"Muller, T. D. et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J.\u00a0Pept. Sci. 18, 383\u2013393 (2012).","journal-title":"J. Pept. Sci."},{"key":"118_CR128","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.2337\/db13-1609","volume":"63","author":"C Clemmensen","year":"2014","unstructured":"Clemmensen, C. et al. GLP-1\/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 63, 1422\u20131427 (2014).","journal-title":"Diabetes"},{"key":"118_CR129","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diabetes.48.7.1487","volume":"48","author":"N Chinookoswong","year":"1999","unstructured":"Chinookoswong, N., Wang, J. L. & Shi, Z. Q. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 48, 1487\u20131492 (1999).","journal-title":"Diabetes"},{"key":"118_CR130","doi-asserted-by":"publisher","first-page":"17391","DOI":"10.1073\/pnas.1008025107","volume":"107","author":"T Fujikawa","year":"2010","unstructured":"Fujikawa, T., Chuang, J. C., Sakata, I., Ramadori, G. & Coppari, R. Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc. Natl Acad. Sci. USA 107, 17391\u201317396 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"118_CR131","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1210\/en.2010-0890","volume":"152","author":"JP German","year":"2011","unstructured":"German, J. P. et al. Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia. Endocrinology 152, 394\u2013404 (2011).","journal-title":"Endocrinology"},{"key":"118_CR132","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1096\/fj.01-0164com","volume":"16","author":"S Hidaka","year":"2002","unstructured":"Hidaka, S. et al. Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. FASEB J. 16, 509\u2013518 (2002).","journal-title":"FASEB J."},{"key":"118_CR133","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1073\/pnas.0909422107","volume":"107","author":"MY Wang","year":"2010","unstructured":"Wang, M. Y. et al. Leptin therapy in insulin-deficient type I diabetes. Proc. Natl Acad. Sci. USA 107, 4813\u20134819 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"118_CR134","doi-asserted-by":"publisher","first-page":"14670","DOI":"10.1073\/pnas.1107163108","volume":"108","author":"BP Cummings","year":"2011","unstructured":"Cummings, B. P. et al. Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type\u00a02 diabetic UCD-T2DM rats. Proc. Natl Acad. Sci.\u00a0USA 108, 14670\u201314675 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"118_CR135","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2337\/db10-1791","volume":"60","author":"HS Moon","year":"2011","unstructured":"Moon, H. S. et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes 60, 1647\u20131656 (2011).","journal-title":"Diabetes"},{"key":"118_CR136","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2337\/db09-1918","volume":"59","author":"JP German","year":"2010","unstructured":"German, J. P. et al. Leptin deficiency causes insulin resistance induced by uncontrolled diabetes. Diabetes 59, 1626\u20131634 (2010).","journal-title":"Diabetes"},{"key":"118_CR137","doi-asserted-by":"publisher","first-page":"828","DOI":"10.2337\/db14-0625","volume":"64","author":"HS Moon","year":"2015","unstructured":"Moon, H. S. et al. Identification and saturable nature of signaling pathways induced by metreleptin in humans: comparative evaluation of in vivo, ex vivo, and in vitro administration. Diabetes 64, 828\u2013839 (2015).","journal-title":"Diabetes"},{"key":"118_CR138","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2337\/dc16-1553","volume":"40","author":"C Vasandani","year":"2017","unstructured":"Vasandani, C., Clark, G. O., Adams-Huet, B., Quittner, C. & Garg, A. Efficacy and safety of metreleptin therapy in patients with type 1 diabetes: a pilot study. Diabetes Care 40, 694\u2013697 (2017).","journal-title":"Diabetes Care"},{"key":"118_CR139","doi-asserted-by":"publisher","first-page":"14070","DOI":"10.1073\/pnas.0806993105","volume":"105","author":"X Yu","year":"2008","unstructured":"Yu, X., Park, B. H., Wang, M. Y., Wang, Z. V. & Unger, R. H. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc. Natl Acad. Sci.\u00a0USA 105, 14070\u201314075 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"118_CR140","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nm.3579","volume":"20","author":"RJ Perry","year":"2014","unstructured":"Perry, R. J. et al. Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat. Med. 20, 759\u2013763 (2014).","journal-title":"Nat. Med."},{"key":"118_CR141","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1172\/JCI82723","volume":"125","author":"GJ Morton","year":"2015","unstructured":"Morton, G. J., Meek, T. H., Matsen, M. E. & Schwartz, M. W. Evidence against hypothalamic-pituitary-adrenal axis suppression in the antidiabetic action of leptin. J.\u00a0Clin. Invest. 125, 4587\u20134591 (2015).","journal-title":"J. Clin. Invest."},{"key":"118_CR142","first-page":"OR09-4","volume":"38","author":"N Ajluni","year":"2017","unstructured":"Ajluni, N. et al. Efficacy of metreleptin therapy in the treatment of fatty liver disease associated with partial lipodystrophy [abstract]. Endocr. Rev. 38, OR09-4 (2017).","journal-title":"Endocr. Rev."},{"key":"118_CR143","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrd.2015.9","volume":"15","author":"C Degirolamo","year":"2016","unstructured":"Degirolamo, C., Sabba, C. & Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15, 51\u201369 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"118_CR144","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.tem.2015.09.007","volume":"26","author":"A Kharitonenkov","year":"2015","unstructured":"Kharitonenkov, A. & DiMarchi, R. FGF21 revolutions: recent advances illuminating FGF21 biology and medicinal properties. Trends Endocrinol. Metab. 26, 608\u2013617 (2015).","journal-title":"Trends Endocrinol. Metab."},{"key":"118_CR145","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich, G. et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333\u2013340 (2013).","journal-title":"Cell Metab."},{"key":"118_CR146","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar, S. et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 23, 427\u2013440 (2016).","journal-title":"Cell Metab."},{"key":"118_CR147","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/nm.3250","volume":"19","author":"BM Owen","year":"2013","unstructured":"Owen, B. M. et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat.\u00a0Med. 19, 1153\u20131156 (2013).","journal-title":"Nat. Med."},{"key":"118_CR148","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1073\/pnas.1200797109","volume":"109","author":"W Wei","year":"2012","unstructured":"Wei, W. et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc. Natl Acad. Sci. USA 109, 3143\u20133148 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"118_CR149","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cmet.2017.09.005","volume":"26","author":"T Lan","year":"2017","unstructured":"Lan, T. et al. FGF19, FGF21, and an FGFR1\/beta-Klotho-activating antibody act on the nervous system to regulate body weight and glycemia. Cell Metab. 26, 709\u2013718 (2017).","journal-title":"Cell Metab."},{"key":"118_CR150","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.celrep.2015.10.021","volume":"13","author":"MM Kwon","year":"2015","unstructured":"Kwon, M. M., O\u2019Dwyer, S. M., Baker, R. K., Covey, S. D. & Kieffer, T. J. FGF21-mediated improvements in glucose clearance require uncoupling protein 1. Cell Rep. 13, 1521\u20131527 (2015).","journal-title":"Cell Rep."},{"key":"118_CR151","doi-asserted-by":"publisher","first-page":"E444","DOI":"10.1152\/ajpendo.00691.2006","volume":"293","author":"J Nedergaard","year":"2007","unstructured":"Nedergaard, J., Bengtsson, T. & Cannon, B. Unexpected evidence for active brown adipose tissue in adult humans. Am. J. Physiol. Endocrinol. Metab. 293, E444\u2013E452 (2007).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"118_CR152","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cmet.2015.12.003","volume":"23","author":"S von Holstein-Rathlou","year":"2016","unstructured":"von Holstein-Rathlou, S. et al. FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver. Cell Metab. 23, 335\u2013343 (2016).","journal-title":"Cell Metab."},{"key":"118_CR153","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar, S. et al. FGF21 regulates sweet and alcohol preference. Cell Metab. 23, 344\u2013349 (2016).","journal-title":"Cell Metab."},{"key":"118_CR154","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.molmet.2017.08.004","volume":"6","author":"BN Desai","year":"2017","unstructured":"Desai, B. N. et al. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Mol. Metab. 6, 1395\u20131406 (2017).","journal-title":"Mol. Metab."},{"key":"118_CR155","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molmet.2018.03.010","volume":"11","author":"S Soberg","year":"2018","unstructured":"Soberg, S. et al. FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest. Mol. Metab. 11, 96\u2013103 (2018).","journal-title":"Mol. Metab."},{"key":"118_CR156","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molmet.2016.11.001","volume":"6","author":"AM Lundsgaard","year":"2017","unstructured":"Lundsgaard, A. M. et al. Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates. Mol. Metab. 6, 22\u201329 (2017).","journal-title":"Mol. Metab."},{"key":"118_CR157","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.cmet.2017.04.009","volume":"25","author":"S Soberg","year":"2017","unstructured":"Soberg, S. et al. FGF21 is a sugar-induced hormone associated with sweet intake and preference in humans. Cell Metab. 25, 1045\u20131053 (2017).","journal-title":"Cell Metab."},{"key":"118_CR158","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature25010","volume":"553","author":"S Lee","year":"2018","unstructured":"Lee, S. et al. Structures of beta-klotho reveal a \u2018zip code\u2019-like mechanism for endocrine FGF signalling. Nature 553, 501\u2013505 (2018).","journal-title":"Nature"},{"key":"118_CR159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038438","volume":"7","author":"AC Adams","year":"2012","unstructured":"Adams, A. C. et al. Fundamentals of FGF19 and FGF21 action in vitro and in vivo. PLOS ONE 7, e38438 (2012).","journal-title":"PLOS ONE"},{"key":"118_CR160","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","volume":"391","author":"SA Harrison","year":"2018","unstructured":"Harrison, S. A. et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 391, 1174\u20131185 (2018).","journal-title":"Lancet"},{"key":"118_CR161","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1172\/JCI70710","volume":"123","author":"GJ Morton","year":"2013","unstructured":"Morton, G. J. et al. FGF19 action in the brain induces insulin-independent glucose lowering. J. Clin. Invest. 123, 4799\u20134808 (2013).","journal-title":"J. Clin. Invest."},{"key":"118_CR162","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1210\/en.2012-1891","volume":"154","author":"KK Ryan","year":"2013","unstructured":"Ryan, K. K. et al. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154, 9\u201315 (2013).","journal-title":"Endocrinology"},{"key":"118_CR163","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/nm.4363","volume":"23","author":"B Benoit","year":"2017","unstructured":"Benoit, B. et al. Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice. Nat. Med. 23, 990\u2013996 (2017).","journal-title":"Nat. Med."},{"key":"118_CR164","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jhep.2017.01.027","volume":"66","author":"M Zhou","year":"2017","unstructured":"Zhou, M. et al. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19\/FGF15. J. Hepatol. 66, 1182\u20131192 (2017).","journal-title":"J. Hepatol."},{"key":"118_CR165","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/hep4.1108","volume":"1","author":"M Zhou","year":"2017","unstructured":"Zhou, M. et al. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol. Commun. 1, 1024\u20131042 (2017).","journal-title":"Hepatol. Commun."},{"key":"118_CR166","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature13540","volume":"513","author":"JM Suh","year":"2014","unstructured":"Suh, J. M. et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 513, 436\u2013439 (2014).","journal-title":"Nature"},{"key":"118_CR167","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nm.4101","volume":"22","author":"JM Scarlett","year":"2016","unstructured":"Scarlett, J. M. et al. Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents. Nat. Med. 22, 800\u2013806 (2016).","journal-title":"Nat. Med."},{"key":"118_CR168","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.cmet.2016.08.003","volume":"24","author":"L Lynch","year":"2016","unstructured":"Lynch, L. et al. iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy. Cell Metab. 24, 510\u2013519 (2016).","journal-title":"Cell Metab."},{"key":"118_CR169","first-page":"S58","volume":"59","author":"HN Hong","year":"2016","unstructured":"Hong, H. N. et al. YH25724, a novel long-acting GLP-1\/FGF21 dual agonist provides potent and sustained glycaemic control, body weight loss and lipid profile improvement in animal models [abstract 111]. Diabetologia 59, S58 (2016).","journal-title":"Diabetologia"},{"key":"118_CR170","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.cmet.2011.12.013","volume":"15","author":"KK Ryan","year":"2012","unstructured":"Ryan, K. K., Woods, S. C. & Seeley, R. J. Central nervous system mechanisms linking the consumption of palatable high-fat diets to the defense of greater adiposity. Cell Metab. 15, 137\u2013149 (2012).","journal-title":"Cell Metab."},{"key":"118_CR171","first-page":"2583","volume":"118","author":"M Rosenbaum","year":"2008","unstructured":"Rosenbaum, M., Sy, M., Pavlovich, K., Leibel, R. L. & Hirsch, J. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J. Clin. Invest. 118, 2583\u20132591 (2008).","journal-title":"J. Clin. Invest."},{"key":"118_CR172","first-page":"457","volume":"29","author":"EA Sims","year":"1973","unstructured":"Sims, E. A. et al. Endocrine and metabolic effects of experimental obesity in man. Recent Prog. Horm. Res. 29, 457\u2013496 (1973).","journal-title":"Recent Prog. Horm. Res."},{"key":"118_CR173","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/ajcn\/56.4.641","volume":"56","author":"EO Diaz","year":"1992","unstructured":"Diaz, E. O., Prentice, A. M., Goldberg, G. R., Murgatroyd, P. R. & Coward, W. A. Metabolic response to experimental overfeeding in lean and overweight healthy volunteers. Am. J. Clin. Nutr. 56, 641\u2013655 (1992).","journal-title":"Am. J. Clin. Nutr."},{"key":"118_CR174","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.cmet.2014.09.002","volume":"20","author":"Y Ravussin","year":"2014","unstructured":"Ravussin, Y., Leibel, R. L. & Ferrante, A. W. Jr. A missing link in body weight homeostasis: the catabolic signal of the overfed state. Cell Metab. 20, 565\u2013572 (2014).","journal-title":"Cell Metab."},{"key":"118_CR175","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"O\u2019Neil, P. M. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392, 637\u2013649 (2018).","journal-title":"Lancet"},{"key":"118_CR176","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","volume":"298","author":"S Singh","year":"2007","unstructured":"Singh, S., Loke, Y. K. & Furberg, C. D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298, 1189\u20131195 (2007).","journal-title":"JAMA"},{"key":"118_CR177","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod, M. et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation 136, 249\u2013259 (2017).","journal-title":"Circulation"},{"key":"118_CR178","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J.\u00a0Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"118_CR179","doi-asserted-by":"publisher","unstructured":"Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X (2018).","DOI":"10.1016\/S0140-6736(18)32261-X"},{"key":"118_CR180","first-page":"1798","volume":"375","author":"JB Buse","year":"2016","unstructured":"Buse, J. B. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 1798\u20131799 (2016).","journal-title":"N. Engl. J. Med."},{"key":"118_CR181","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247\u20132257 (2015).","journal-title":"N. Engl. J. Med."},{"key":"118_CR182","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N.\u00a0Engl. J. Med. 377, 1228\u20131239 (2017).","journal-title":"N. Engl. J. Med."},{"key":"118_CR183","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.tem.2018.01.011","volume":"29","author":"S Lim","year":"2018","unstructured":"Lim, S., Kim, K. M. & Nauck, M. A. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol. Metab. 29, 238\u2013248 (2018).","journal-title":"Trends Endocrinol. Metab."},{"key":"118_CR184","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/jc.2015-3133","volume":"101","author":"CL Moller","year":"2016","unstructured":"Moller, C. L. et al. Glucose-dependent insulinotropic polypeptide is associated with lower low-density lipoprotein but unhealthy fat distribution, independent of insulin: the ADDITION-PRO study. J. Clin. Endocrinol. Metab. 101, 485\u2013493 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"118_CR185","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.cmet.2017.11.003","volume":"27","author":"JR Ussher","year":"2018","unstructured":"Ussher, J. R. et al. Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction. Cell Metab. 27, 450\u2013460 (2018).","journal-title":"Cell Metab."},{"key":"118_CR186","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.molmet.2018.05.014","volume":"14","author":"F Kahles","year":"2018","unstructured":"Kahles, F. et al. The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE\u2212\/\u2212 mice by blocking monocyte\/macrophage activation. Mol. Metab. 14, 150\u2013157 (2018).","journal-title":"Mol. Metab."},{"key":"118_CR187","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03586830 (2018)."},{"key":"118_CR188","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03486392 (2018)."},{"key":"118_CR189","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03235050 (2018)."},{"key":"118_CR190","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03244800 (2018)."},{"key":"118_CR191","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02492763 (2018)."},{"key":"118_CR192","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02973321 (2018)."},{"key":"118_CR193","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03437720 (2018)."},{"key":"118_CR194","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02119819 (2016)."},{"key":"118_CR195","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03406377 (2018)."},{"key":"118_CR196","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03308721 (2017)."},{"key":"118_CR197","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02692781 (2018)."},{"key":"118_CR198","unstructured":"ZealandPharma. Zealand and Boehringer Ingelheim to change development program on novel dual-acting glucagon\/GLP-1 receptor agonists to treat Type 2 diabetes and\/or obesity with a new lead compound that will replace ZP2929. Zealand Pharma Company Release https:\/\/cws.huginonline.com\/Z\/136974\/PR\/201401\/2026559_5.html (2014)."},{"key":"118_CR199","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03175211 (2018)."},{"key":"118_CR200","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03591718 (2018)."},{"key":"118_CR201","unstructured":"Eli Lilly and Company. Q2 2018 earnings. Lilly Investors https:\/\/investor.lilly.com\/static-files\/3556875d-ae48-4911-99ba-05647b225ed5 (2018)."},{"key":"118_CR202","unstructured":"Kamal, S. Spitfire Pharma\u2019s SP-1373 outscored semaglutide and elafibranor in a biopsy-proven translational mouse model of non-alcoholic steatohepatitis (NASH). Velocity Pharmaceutical Development http:\/\/www.vpd.net\/press_releases\/VPD_1.4.2018.html (2018)."},{"key":"118_CR203","first-page":"A274","volume":"65","author":"S You","year":"2016","unstructured":"You, S. et al. Long-acting GLP-1 and glucagon receptor dual agonists for the treatment of type 2 diabetes. Diabetes 65, A274 (2016).","journal-title":"Diabetes"},{"key":"118_CR204","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03311724 (2018)."},{"key":"118_CR205","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03131687 (2018)."},{"key":"118_CR206","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02205528 (2018)."},{"key":"118_CR207","unstructured":"Sanofi. Q2 2018 performance positions Sanofi for new growth phase. Hugin.info http:\/\/hugin.info\/152918\/R\/2208107\/858824.pdf (2018)."},{"key":"118_CR208","first-page":"A528","volume":"64","author":"CB Knudsen","year":"2015","unstructured":"Knudsen, C. B. et al. An optimized novel GLP-1-GIP receptor dual agonist with potent effects on body weight and glucose control in mice has the potential for once-weekly administration in humans. Diabetes 64, A528 (2015).","journal-title":"Diabetes"},{"key":"118_CR209","unstructured":"SCOHIA PHARMA, Inc. SCO-094. SCOHIA PHARMA, Inc. Pipeline https:\/\/www.scohia.com\/eng\/sys\/pipeline\/sco-094 (2017)."},{"key":"118_CR210","unstructured":"Hansen, S. K. Carmot Therapeutics announces close of series B financing. Carmot Therapeutics http:\/\/carmot-therapeutics.us\/2018\/01\/16\/carmot-therapeutics-announces-close-of-series-b-financing (2018)."},{"key":"118_CR211","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03374241 (2018)."},{"key":"118_CR212","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03661879 (2018)."},{"key":"118_CR213","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03095807 (2017)."},{"key":"118_CR214","unstructured":"Sanofi. Sustaining innovation analyst day. Sanofi https:\/\/www.sanofi.com\/media\/Project\/One-Sanofi-Web\/sanofi-com\/en\/investors\/docs\/Sustaining_innovation_day_2017_presentation_appendices_Web.pdf (2017)."},{"key":"118_CR215","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03230786 (2018)."},{"key":"118_CR216","unstructured":"Eli Lilly and Company. Medicines in development \u2014 molecule and potential indication data as of July 17, 2018. Lilly Discovery https:\/\/www.lilly.com\/discovery\/pipeline (2018)."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-018-0118-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-018-0118-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-018-0118-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T04:20:40Z","timestamp":1650428440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-018-0118-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":216,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["118"],"URL":"https:\/\/doi.org\/10.1038\/s41574-018-0118-x","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"16 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C., T.D.M. and S.M.H. declare no competing interests. M.H.T has served as SAB member of ERX Pharmaceuticals. The Institute for Diabetes and Obesity cooperates with Novo Nordisk and Sanofi-Aventis. B.F. and R.D.D. are currently employees of Novo Nordisk.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}